Most research supports doses between 200-400 mcg daily for general metabolic support, while specialized applications may utilize higher doses up to 1000 mcg
GLP-1 and GIP receptor agonists such as tirzepatide (Zepbound and Mounjaro) can also be used for weight loss and type 2 diabetes management
While the gastrointestinal effects (nausea, diarrhea, vomiting) are similar to other GLP-1 medications like Wegovy and Mounjaro, retatrutide has one unique finding: dysesthesia (abnormal touch sensations) in 20.9% of patients at the 12mg dose in TRIUMPH-4, and 12.5% at 12mg in the larger TRIUMPH-1 trial
They must also test compounded medicines and products for potency, sterility, and purity
(4) Clinical combinations: BBR-silymarin co-administration significantly improves glycemic control (fasting glucose, HOMA-IR) and lipid profiles (TG, LDL) in diabetic patients, and decreases BMI, and the WHR in obesity patients versus BBR monotherapy [196]
GLP-1 injections typically cause less discomfort than many other injectable medications due to their very fine needles (2932 gauge) and short length (48 mm)